Arcellx Stock Statistic Functions Linear Regression Angle

ACLX Stock  USD 114.51  0.12  0.10%   
This statistic functions tool runs Linear Regression Angle function and companion studies for Arcellx. The analysis highlights statistical functions describing dispersion and variability and frames technical signals with volatility and risk context.Please specify Time Period to run the technical study.

Execute Function
This analysis covers thirty-eight data points across the selected time horizon. The Linear Regression Angle indicator plots the angel of the trend line for each Arcellx data point.

Arcellx Technical Analysis Modules

Most technical analysis of Arcellx help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Arcellx from various momentum indicators to cycle indicators. When you analyze Arcellx charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

Stock Overview, Methodology & Data Sources

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland. Arcellx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 78 people. This overview emphasizes how Arcellx compares to peers on valuation quality and operating consistency. Current metrics include P/B of 16.63. Arcellx has a market cap of 6.69 B, ROE of -53.42%.

Methodology

Unless otherwise specified, financial data for Arcellx is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Arcellx (USA Stocks:ACLX) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: We primarily rely on public filings and market reference sources, including disclosures published by U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Data is normalized for analytical consistency across reporting formats. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.

Analyst Sources

Arcellx has active sell-side coverage. Source-validated coverage currently shows 18 approved analysts, while broader market-consensus totals may differ across providers due to methodology and update timing. 9 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Morgan Stanley, Oppenheimer & Co., RBC Capital Markets, J.P. Morgan, Wells Fargo Securities, Guggenheim Securities, Deutsche Bank, Raymond James, Citigroup, HSBC Global Research, among others. Updates may occur throughout the day.

This content is curated and reviewed by:

Gabriel Shpitalnik - Member of Macroaxis Editorial Board
Last reviewed on March 7th, 2026

Align your values with your investing style

With 6.69 Billion market cap in the Biotechnology industry, Arcellx works well as a smaller-cap core holding around which broader thematic baskets can be built. Anchoring a Biotechnology theme around Arcellx at 6.69 Billion can be tuned for upside participation or tighter downside control depending on Healthcare outlook.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Trending Themes

If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment.
Investor Favorites Idea
Investor Favorites
Invested few shares
Macroaxis Index Idea
Macroaxis Index
Invested over 60 shares
Momentum Idea
Momentum
Invested over 40 shares
Blockchain Idea
Blockchain
Invested few shares
Artificial Intelligence Idea
Artificial Intelligence
Invested few shares
Warren Buffett Holdings Idea
Warren Buffett Holdings
Invested few shares
Dividend Beast Idea
Dividend Beast
Invested over 40 shares
Corona Opportunity Idea
Corona Opportunity
Invested few shares
Hedge Favorites Idea
Hedge Favorites
Invested over 20 shares
Cash Cows Idea
Cash Cows
Invested few shares
ESG Investing Idea
ESG Investing
Invested few shares

More Resources for Arcellx Stock Analysis

A comprehensive view of Arcellx starts with financial statements and ratio context. Key ratios help frame profitability, efficiency, and growth context for Arcellx Stock. Outlined below are key reports that provide context for Arcellx Stock:
Arcellx has a market cap of 6.69 B, operating margin of -38.5%, ROE of -53.42%. Trending Equities can help frame allocation decisions. This reflects a position in Arcellx inside the allocation mix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
Our How to Invest in Arcellx guide provides practical guidance on trading Arcellx Stock.
Arcellx currently shows ROE of -53.42%, market cap of 6.69 Billion. Arcellx analysis should be paired with portfolio risk and diversification tools before adjusting allocations. Arcellx analysis across multiple dimensions - risk, valuation, diversification - produces a more informed position-sizing decision. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
 Earnings Share
-4.07
 Revenue Per Share
0.396
 Quarterly Revenue Growth
-0.89
 Return On Assets
-0.24
 Return On Equity
-0.53
Understanding Arcellx includes distinguishing between market value and book value, where book value reflects Arcellx's accounting equity. Arcellx's market capitalization is 6.69 B. The 16.63 P/B ratio shows Arcellx carries a substantial premium over its balance-sheet equity. Enterprise value stands at 6.29 B. Value and price for Arcellx are related but not identical, and they can diverge across cycles. Trading price represents the transaction level agreed by market participants.
The concept of value for Arcellx differs from its quoted price, since each reflects a different lens. For Arcellx, key inputs include a P/B ratio of 16.63, ROE of -53.42%, and revenue of 22.29 M. Arcellx's trading price represents the transaction level agreed by market participants.